Bright Minds Biosciences Inc (DRUG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.50 Million) by net assets ($308.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Bright Minds Biosciences Inc for the company's overall valuation and market capitalisation.
Bright Minds Biosciences Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bright Minds Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bright Minds Biosciences Inc ranked by their cash flow conversion efficiency. Explore DRUG cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Janus International Group Inc
NYSE:JBI
|
0.063x |
|
Goldcard High-Tech Co Ltd
SHE:300349
|
0.046x |
|
Phathom Pharmaceuticals Inc
NASDAQ:PHAT
|
0.033x |
|
Cloudberry Clean Energy As
OL:CLOUD
|
0.013x |
|
Qingdao Hiron Commercial Cold Chain Co Ltd
SHG:603187
|
0.075x |
|
Zero One Technology Co Ltd
TW:3029
|
-0.013x |
|
Solusi Sinergi Digital Tbk PT
JK:WIFI
|
0.018x |
|
PPC Ltd
JSE:PPC
|
0.136x |
Annual Cash Flow Conversion Efficiency for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Bright Minds Biosciences Inc from 2019 to 2025. View current stock price of Bright Minds Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $82.04 Million | $-8.69 Million | -0.106x | +68.30% |
| 2024-09-30 | $5.54 Million | $-1.85 Million | -0.334x | +68.61% |
| 2023-09-30 | $6.60 Million | $-7.02 Million | -1.065x | +17.40% |
| 2022-09-30 | $10.54 Million | $-13.59 Million | -1.289x | -241.63% |
| 2021-09-30 | $19.40 Million | $-7.32 Million | -0.377x | +4.60% |
| 2020-09-30 | $729.29K | $-288.39K | -0.395x | -19.80% |
| 2019-09-30 | $127.26K | $-42.01K | -0.330x | -- |
About Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more